Skip to content

Free cash flow at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$848.3M+4.0%
HRO
HarrowHROW
-$9.19M-147%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$119.68M-29.0%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$70.66M-51.6%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
-$60.94M-146%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$106.52M-95.1%

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Calculated from Kodiak Sciences Inc’s reported figures.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's free cash flow?
Kodiak Sciences Inc (KOD) reported free cash flow of -$40.95M in Q1 2026.
How has Kodiak Sciences Inc's free cash flow changed year-over-year?
Kodiak Sciences Inc's free cash flow decreased by 39.5% year-over-year, from -$29.35M to -$40.95M.
What is the long-term trend for Kodiak Sciences Inc's free cash flow?
Over 4 years (2021 to 2025), Kodiak Sciences Inc's free cash flow has grown at a -9.0% compound annual growth rate (CAGR), from -$199.3M to -$136.51M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.